RECRUITING

The Neonatal Hemorrhagic Risk Assessment in Thrombocytopenia

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This is a prospective observational study designed to evaluate Immature Platelet Fraction or Immature Platelet Count and Platelet Function Analyzer-100/200 Closure Time-ADP (in vitro bleeding time) as markers of bleeding risk in thrombocytopenic preterm neonates admitted to the Neonatal Intensive Care Unit.

Official Title

The Neonatal Hemorrhagic Risk Assessment in Thrombocytopenia Study-2

Quick Facts

Study Start:2021-06-15
Study Completion:2025-12-31
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT04598750

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:1 Day
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:CHILD, ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Have a gestational age \<32 weeks and a birth weight ≥500 grams;
  2. * Have a platelet count \<100 x 109/L; and
  3. * Have a parent/guardian willing to provide written informed consent.
  1. * Are not expected to survive for \>24 hours by the Attending Neonatologist;
  2. * Are thought to have a familial thrombocytopenia or platelet dysfunction, based on family history or clinical presentation (associated congenital malformations, platelet morphology).

Contacts and Locations

Study Contact

Emöke Deschmann, MD, PhD
CONTACT
+46 73 539 5575
emoke.deschmann@regionstockholm.se
Martha Sola-Visner, MD
CONTACT
617-919-4845
martha.sola-visner@childrens.harvard.edu

Principal Investigator

Emöke Deschmann, MD, PhD
PRINCIPAL_INVESTIGATOR
Karolinska Institutet
Robert Christensen, MD
STUDY_CHAIR
University of Utah Medical Center

Study Locations (Sites)

Boston Children's Hospital
Boston, Massachusetts, 02115
United States
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02215
United States
Intermountain Medical Center
Murray, Utah, 84107
United States
Utah Valley Hospital
Provo, Utah, 84604
United States

Collaborators and Investigators

Sponsor: Karolinska Institutet

  • Emöke Deschmann, MD, PhD, PRINCIPAL_INVESTIGATOR, Karolinska Institutet
  • Robert Christensen, MD, STUDY_CHAIR, University of Utah Medical Center

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2021-06-15
Study Completion Date2025-12-31

Study Record Updates

Study Start Date2021-06-15
Study Completion Date2025-12-31

Terms related to this study

Additional Relevant MeSH Terms

  • Neonatal Thrombocytopenia
  • Bleeding